Biohaven (BHVN) Net Cash Flow Growth (3y) (2024 - 2026)

Biohaven (BHVN) Net Cash Flow Growth (3y) (2024 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) NCF Growth (3y) (Qtr)
1 Oculis Holding AG 66,320.50 Bn 66,320.21 Bn - -50.33%
2 Nanobiotix 1,933.82 Bn 1,933.76 Bn - -
3 Akari Therapeutics 1,022.34 Bn 1,022.34 Bn - -
4 BeOne Medicines 472.93 Bn 468.14 Bn 1.35 Bn 38.47%
5 Vertex Pharmaceuticals 122.22 Bn 114.98 Bn 2.59 Bn 33.37%
6 Regeneron Pharmaceuticals 69.96 Bn 61.21 Bn 3.31 Bn -29.82%
7 Belite Bio 62.66 Bn 62.66 Bn - -
8 Argenx Se 56.07 Bn 50.89 Bn 1.41 Bn -
9 Alnylam Pharmaceuticals 37.60 Bn 34.59 Bn 959.66 Mn 32.17%
10 Biohaven 2.16 Bn 1.81 Bn - 41.81%

Historic Data

Download Data
DateValue
Mar 31, 2026 41.81%
Dec 31, 2025 -38.49%
Sep 30, 2025 -10.98%
Jun 30, 2025 80.61%
Mar 31, 2025 26.06%
Dec 31, 2024 27.04%